NewLink Genetics

NAS:NLNK

Biotechnology

Market Cap

$61.51mm

SMALL cap

Share Price ↓

$1.61 (-2.42%)

YTD Return ↓

-0.6024%

since start of 2019

P/E Ratio

—

NLNK chart by TradingView

Source: FactSet financial data and analytics.

Corporate Values

Carbon Footprint
Pollution Prevention
Water Conservation
Data Privacy
Consumer Health
Employee Satisfaction
Workplace Safety
Corp Gov
Ethical Practices
Conflict Materials
Forced Labor
Gender Diversity

Legend

About

Biotechnology Founded 1999

NewLink Genetics Corp. is a clinical stage immuno-oncology company, which focuses on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. The company's products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189 and IDO Pathway Inhibitors. NewLink Genetics was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.

website

Source: FactSet Research Systems

Headquarters

2503 South Loop Drive

Suite 5100

Ames, IA 50010

1.515.296.5555

Executives

Name	Title	Gender
John B. Henneman, III	Chief Financial Officer, Secretary & Executive VP	Male
Thomas P. Monath, MD	Chief Scientific Officer	Male
Charles J. Link, MD	Chairman, Chief Executive & Scientific Officer	Male
Nicholas N. Vahanian, MD, MBA	President, Director & Chief Medical Officer	Male
Eugene P. Kennedy	Vice President-Clinical & Medical Affairs	Male
Eugene Sackett	Vice President-Human Resources	Male

Mindful Investing Summary

Legend

Carbon Footprint — N/A

NewLink Genetics among its competitors for its carbon footprint. A company’s performance in this category is based on its success in implementing energy efficiency measures. Investments in energy efficient technology, green building and sourcing of renewable energy can all lead to cost savings and reduce the company’s contribution to climate change.
Pollution Prevention — N/A

NewLink Genetics on this issue. Companies are evaluated on pollution prevention by the levels of waste (including hazardous waste) they produce and release into the environment, and can be affected by whether they develop products that can reduce exposure to pollution.
Water Conservation — N/A

NewLink Genetics among its peers in this category. A company’s score in this category depends on its measures to minimize water usage and impacts on stressed or drought-prone water resources.
Data & Privacy Protection — N/A

NewLink Genetics among its peers and competitors for data privacy and protection. Companies today digitally manage vast amounts of personal information about their clients. A company’s score on this issue is based on the systems, products and procedures it has in place to minimize the risk for data and privacy breaches.
Consumer Health, Wellness & Safety — N/A

NewLink Genetics compared to its peers and competitors Companies in this category manage its product and safety risks.
Employee Ownership, Satisfaction, Benefits & Pay — N/A

NewLink Genetics among its peers for employee satisfaction and pay. A company’s score on this issue depends on its frequency and likelihood of labor disputes as well as its practices to keep and retain talent - such as compensation, family leave, employee health care and other benefits. Employers that are rated as good to work for consistently produce higher stock returns than their peers.
Workplace Health and Safety — N/A

NewLink Genetics among its competitors on this issue. A company’s workplace health and safety is evaluated not only by the number of accidents and injuries in the workplace, but also by their safety policies, training procedures, and their investment in equipment that can reduce accidents.
Integrity of Corporate Governance — N/A

NewLink Genetics among its competitors on corporate governance. This score is determined by the company’s accounting practices, executive pay, board organization and ownership structure.
Ethical Practices — N/A

NewLink Genetics compared to its peers and competitors. A company’s rating on this issue is based on its history of controversies related to unethical corporate behavior, such as false claims about their products, price fixing, executive misconduct, insider trading or fraudulent practices.
Usage of Conflict Materials — N/A

NewLink Genetics among its competitors in this category. Certain products use raw materials that are commonly sourced from militias or other organizations that promote or engage in conflict in their region. To perform well in this category companies must provide adequate assurances that any of these metals used in their production are in fact from conflict-free sources.
Forced Labor — N/A

NewLink Genetics compared to its competitors on forced labor. A company’s score on this issue depends on its use of forced labor and on its work conditions for outsourced labor.
Diversity of Corporate Leadership 2 N/A

NewLink Genetics performs poorly based on its peers as well as companies in similar geographic regions. Companies are assessed on factors such as board diversity and senior management diversity. Companies performing well on this issue typically are more profitable than its peers, while companies with very poor scores typically have greater stock price volatility and lower returns on capital.

NewLink Genetics - Competitors and Related Companies

How NewLink Genetics stacks up to its peers in the Biotechnology industry or with competing business segments.